FDA-TRACK: Center for Biologics Evaluation and Research - Goal 3
FDA's Center for Biologics Evaluation and Research (CBER) regulates biological products for human use under applicable federal laws, including the Public Health Service Act and the Federal Food, Drug and Cosmetic Act. CBER protects and advances the public health by ensuring that biological products are safe and effective and available to those who need them. CBER also provides the public with information to promote the safe and appropriate use of biological products.
During public health emergencies, the American public relies on CBER to proactively enhance response preparedness. This means the discovery, development, production, and distribution of regulated products to counter these threats and resolve public health emergencies. As many of the products FDA regulates directly address infectious disease threats that are not unique to the U.S., CBER carries out its regulatory responsibilities through international engagements that support both national and global health.
Goal 3: Increase Preparedness for Emerging Threats and Promote Global Public Health
Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons.